Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03674814 · ClinicalTrials.gov registry record · Phase 1

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

A Phase 1 study of Prostate Cancer, sponsored by University of Chicago.

Active
Registry status
Phase 1
Development phase
35
Enrollment target
1
Study location

NCT03674814 is a Phase 1 study of Prostate Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 35 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03674814, a Phase 1 study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Enzalutamide
  • DRUG Relacorilant

Study Locations (1)

Illinois

  • University Of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2018-10-23
Est. Completion 2027-03-10
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03674814

The ClinicalTrials.gov registry entry for NCT03674814 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT03674814 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03674814 about?

NCT03674814 is a clinical study titled "Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer". The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

What is the current status of trial NCT03674814?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-10-23. Estimated completion is 2027-03-10.

What conditions does trial NCT03674814 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03674814?

The interventions under investigation include: Enzalutamide (DRUG), Relacorilant (DRUG).

Who is sponsoring clinical trial NCT03674814?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03674814 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.